
The urgency is real.
And we feel it.
Discover our **bladder and bowel control** portfolio
Inspired innovation • Support that never stops • Trusted outcomes
Medtronic

Bladder control

BY THE NUMBERS

1 in 6 Americans experience symptoms of overactive bladder (OAB)[1,2]

Nearly

16 **million** with UUI in the U.S.[2,3]

That's nearly

43

million people[1-3]

It's estimated that **ONLY**

<4%

of patients with OAB receive advanced therapies.[4,5]

Bowel control

BY THE NUMBERS

1 in 12 Americans experience symptoms of fecal incontinence (FI)[6,7]

That's nearly

21

million people[2,6,7]

An estimated

13

million experience both[1-3,8] (OAB and FI)

The time is now for bladder and bowel control.

Inspired innovation

Because life is measured in moments.

The most extensive neuromodulation portfolio for bladder and bowel control.

IMPLANTABLE TIBIAL NEUROMODULATION

A simple experience

Altaviva™ system

For patients with UUI

- No sedation or imaging required[9]
- Expected 15 years of battery life[†,10]
- Full-body[‡] MRI ready from the start[9]

In addition to risks related to surgery, complications can include pain at the implant site, infection, reaction to local anesthesia, wound complications, lower leg pain, nerve injury, movement of the implant, adverse change in bowel or urinary function, uncomfortable or unintended stimulation sensations, loss of therapeutic effect, discomfort during recharge, or technical or device problems. Please refer to Important Safety Information for more details.

† Based on clinical and bench testing for expected therapy settings.
‡ Under certain conditions; see approved labeling for details.

SACRAL NEUROMODULATION

Proven technology, durable outcomes.[11-13]

InterStim™ X system

For patients with OAB, NOUR, and FI

- Basic evaluation leads uniquely designed to minimize electrode migration during daily activities[14,15]
- Expected up to 10 years of battery life,[§] and at low energy settings up to 15 years[◊]
- Full-body[‡] 1.5T and 3T MRI compatible[16]

In addition to risks related to surgery, complications can include pain at the implant sites, new pain, infection, lead (thin wire) movement/migration, device problems, undesirable changes in urinary or bowel function, and uncomfortable stimulation (sometimes described as a jolting or shocking feeling). Please refer to Important Safety Information for more details.

§ Under expected therapy settings and telemetry use.
◊ Please see System Eligibility, Battery Longevity, Specifications manual for battery longevity estimates.
‡ Under certain conditions; see approved labeling for details.

PERCUTANEOUS TIBIAL NEUROMODULATION

NURO™ system

For patients with OAB

Quick, in-office therapy

- Easy therapy delivery
- 30-minute therapy sessions
- 12 weekly sessions, then monthly maintenance sessions

Most common side effects of PTNM are temporary and include mild pain or skin inflammation at or near the stimulation site.

Giving you and your patients more choices.



DIGITAL HEALTH SOLUTION

MyFuture™ digital app

Education | Tracking | Reporting

- Voiding diary collection and review
- Personalized patient education
- Physician portal designed to streamline your experience

Broad MRI compatibility

Unparalleled expertise. Unmatched access.

- Altaviva™ system – **Full-body† MRI** ready from the start[9]
- InterStim™ systems – **Full-body† 1.5T and 3T MRI compatible**
  The **only** sacral neuromodulation systems that provide **MRI access** without impedance disqualifiers.[16,17]

† Under certain conditions; see approved labeling for details.



20+ years
of MRI innovation

1.2M
unique scanning scenarios

10M+
simulated scans

Exclusive Medtronic battery technology

Powered by ~70 years of expertise

From pacemakers to neurostimulators – our Altaviva™ and InterStim™ device batteries offer the same reliability as our life-changing pacemakers.

Engineered not outsourced.

Altaviva™ system
Implantable tibial neuromodulation (ITNM)

InterStim™ X system
Sacral neuromodulation (SNM)

From originator to innovator

The same **passion** that inspired us to originate neuromodulation for bladder and bowel control **drives our innovation today.**



MyFuture™
digital app

DIGITAL HEALTH SOLUTION

Education | Tracking | Reporting

- Voiding diary collection and review
- Personalized patient education
- Physician portal designed to streamline your experience

The MyFuture™ app provides **digital diary and education tools for patients with bladder and bowel control symptoms.**

- **When questions arise, the MyFuture™ app answers.** The app provides patients timely, personalized information before, during and after their evaluation and implant procedure.
- **When your patients leave your office, help them remember what you talked about.** The MyFuture™ app lets them review key information whenever they need it.

Available in English and Spanish.

Paper diaries can be cumbersome.

That's why the MyFuture™ app offers a **convenient, easy, and discreet** way for patients to track their symptoms.

The MyFuture™ app offers reports for OAB, UUI, FI and NOUR.

OVER
1M
entries have been made in the digital diary by users of the MyFuture™ app.



The MyFuture™ app generates a **simple report using data entered by your patient.** Review it prior to an appointment and use it to guide an insight-driven conversation.

Support that never stops

Because every moment in care matters.

Comprehensive, end-to-end support across the care continuum.

Full patient journey and device support

From pre-auth to post-implant care

- In-house prior authorization support
- Support Link™ outreach to InterStim™ system patients
- Proactive post-implant device education calls
- 24/7 MRI technical support



Robust clinician training, education, and support

Tailored to best meet your needs

- Digital, on-demand, and in-person education
- Advanced practice provider education
- Fellow and resident education programs
- Seasoned health economic managers

Patient-centered awareness, education, and support

To help you reach more patients

- Therapy awareness partnerships
- Physician finder
- Patient ambassador program
- MyFuture™ app symptom tracking, education, and support

Trusted outcomes

Because freedom is the most powerful outcome.

Backed by 30 years of clinical data for urinary control conditions[18] and 20 years of clinical data for bowel control.[19]

IMPLANTABLE TIBIAL NEUROMODULATION

Treatment for
UUI

Altaviva™
system

80% of Altaviva™ patients reported their **condition had improved† after 12 months** compared to before their implant[9]

61% of Altaviva™ patients reported a **50% or greater improvement** in their symptoms[20]

Altaviva device: Adverse events related to the device, procedure, and/or therapy occurred in 20% of implanted subjects through 12-month follow-up. The most common types of related AEs were implant-related infections at the implant site (7%) and implant site pain (3%).

† As assessed by the Patient Global Impression of Improvement (PG-I)

PERCUTANEOUS TIBIAL NEUROMODULATION

70% reduction in reported in UUI episodes per day at completion of 12 PTNM sessions[20]

Treatment for
OAB

NURO™
system

Most common side effects of PTNM are temporary and include mild pain or skin inflammation at or near the stimulation site.

SACRAL NEUROMODULATION

Treatment for
OAB | NOUR | FI

InterStim™ X
system

82% of InterStim™ OAB patients‡,[11] and **89%** of InterStim™ FI patients reported **sustained improvements after 5 years**§,[13]

InterStim systems: There were no unanticipated adverse device effects. The most common AEs were: undesirable change in stimulation (22%, 60/272); implant site pain (15%, 40/272); and therapeutic product ineffective (13%, 36/272).

‡ Numbers reflect completers analyses defined as patients with diary data at baseline and 5 years.
§ Numbers reflect completers analysis which included patients who had complete data at baseline and at annual visits. Clinical success was 69% and complete continence was 28% in the adjusted worst-case analysis in which patients with missing data due to lack of efficacy, device or therapy-related adverse events, or death were assumed no change from baseline. If data was missing for any other reason at 5 years, the last observation was used. Restored function defined as ≥50% reduction in dysfunctional voiding symptoms from baseline.

Time-tested results that change lives

25+ years of innovation

1K+ clinical publications

450K+ patients treated with InterStim™ systems

#1 Sacral neuromodulation device choice globally for OAB and FI patients[21]

Not having to let my bladder control me lets me go out more… do more things.

It’s just the freedom.

Fran
Altaviva™ system patient

Individual results may vary.
Altaviva™ device: Adverse events related to the device, procedure, and/or therapy occurred in 20% of implanted subjects through 12-month follow-up. The most common types of related AEs were implant-related infections at the implant site (7%) and implant site pain (3%).

Morgon
InterStim™ system patient

InterStim has helped me feel better about my life.

And it continues to allow me to do the things I know I wouldn’t be able to do without it.

Individual results may vary.
InterStim™ systems: There were no unanticipated adverse device effects. The most common AEs were: undesirable change in stimulation (22%, 60/272); implant site pain (15%, 40/272); and therapeutic product ineffective (13%, 36/272).

The time is now for bladder and bowel control.

You’re here for the hard calls, the quiet progress, and the breakthrough moments. We’re here with inspired innovation, support that never stops, and trusted outcomes.

Together, we build for the moments that change lives.

Important safety information

Tibial Neuromodulation delivered by the Altaviva™ system is indicated for treatment of urge urinary incontinence (UUI) in patients who failed or could not tolerate more conservative treatments.

Contraindications: Poor surgical candidates including patients with skin lesions or compromised skin integrity; current or recent history of venous insufficiency and/or venous stasis ulcers in the lower leg; anatomical defects or previous surgeries at the implant site which preclude use of the device. Patients who are not able to operate or receive assistance in operating the system.

Warnings: This therapy is not intended for patients who are considered poor candidates for surgery or are at risk for poor wound healing including, but not limited to, severe uncontrolled diabetes, clinically significant edema in the lower leg, clinically significant peripheral neuropathy, nerve damage, or a neurological condition affecting the lower leg. Do not implant the neurostimulator within 5 cm of another metal implant. This therapy is also not intended for patients with current or unresolved mechanical obstruction such as caused by benign prostatic hypertrophy, cancer, or urethral strictures, or patients with known allergies to any of the materials in the Altaviva™ neurostimulator. Continuous stimulation should not be used as safety and effectiveness have not been established. Safety and effectiveness have also not been established for pregnant women; patients under the age of 18; patients with progressive, systemic neurologic disease; patients with history of urinary retention; bilateral leg stimulation. Diathermy (shortwave and microwave) should not be used on patients with a neurostimulator, as it can cause tissue damage or device damage. The Altaviva™ system may affect the operation of other implanted or external systems. The Altaviva™ system may interfere with the operation of other implanted cardiac devices such as pacemakers and defibrillators. Recharging the neurostimulator within 5 cm of a metal implant may cause recharge heating leading to tissue damage. Do not use the recharger or ankle band in direct contact with an unhealed wound.

MRI Warnings: Prior to an MRI scan, determine if the patient has multiple active or abandoned medical device implants. The most restrictive MRI exposure requirement must be used. MRI scans with another metal implant less than 3 cm away from the Altaviva™ neurostimulator have not been tested, and scanning may cause excessive tissue heating surrounding the device resulting in tissue damage and possible need for surgical intervention.

Adverse Events: In addition to the risks normally associated with surgery, adverse events may include pain at the implant site, infection, reaction to local anesthesia, wound complications, lower leg pain, nerve injury, movement of the implant, adverse change in bowel or urinary function, uncomfortable or unintended stimulation sensations or an inappropriate shock sensation, loss of therapeutic effect, discomfort during recharge, or technical or device problems.

For full prescribing information, refer to the product manuals at www.medtronic.com. Product manuals must be reviewed prior to use for detailed disclosure. USA Rx Only. Rev 0925

Sacral Neuromodulation delivered by the InterStim™ system for Urinary Control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments.

Contraindications: Diathermy. Patients who have not demonstrated an appropriate response to test stimulation or are unable to operate the neurostimulator.

Warning: This therapy is not intended for patients with mechanical obstruction such as benign prostatic hypertrophy, cancer, or urethral stricture.

Warnings/Precautions/Adverse Events:

Safety and effectiveness have not been established for bilateral stimulation; pregnancy, unborn fetus, and delivery; pediatric use under the age of 16; or for patients with neurological disease origins. The system may be affected by or adversely affect cardiac devices, electrocautery, defibrillators, ultrasonic equipment, radiation therapy, MRI, theft detectors/ screening devices. Adverse events include pain at the implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations, including jolting or shock sensations. Patients should be assessed preoperatively for the risk of increased bleeding. For full prescribing information, please call Medtronic at 1-800-328-0810 and/or consult Medtronic's website at www.medtronic.com. Product technical manual must be reviewed prior to use for detailed disclosure.
USA Rx Only. Rev 0517

Indication for Use: Medtronic NURO™ Percutaneous Tibial Neuromodulation is intended to treat patients with overactive bladder and associated symptoms of urinary urgency, urinary frequency, and urge incontinence. Contraindications: Do not use on patients with pacemakers or implantable defibrillators, patients prone to excessive bleeding, patients with nerve damage that could impact either percutaneous tibial nerve or pelvic floor function, or on patients who are pregnant or planning pregnancy. Warnings/Precautions/Adverse Events: Do not use if the skin in the area of use is compromised. Exercise caution for patients with heart problems. Adverse events are typically temporary, and include mild pain, minor inflammation and bleeding near treatment site.

For full prescribing information, please call Medtronic at 1-800-328-0810 and/or consult Medtronic's website at professional.medtronic.com/NURO. Product technical manual must be reviewed prior to use for detailed disclosure. USA Rx only. Rev 0915

1. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. *World J Urol*. 2003;20(6):327-336.
2. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data, 2024. https://www.cdc.gov/nchs/nhanes/Default.aspx. Accessed January 13, 2025.
3. US Census Bureau 2020. US adult and under-age-18 populations: 2020 census. https://www.census.gov/library/visualizations/interactive/adult-and-under-the-age-of-18-populations-2020-census.html. Accessed January 31, 2025.
4. Muller N. What Americans understand and how they are affected by bladder control problems: highlights of recent nationwide consumer research. *Urologic Nurs*. 2005;25(2):109-115.
5. Jericevic D, Shapiro K, Bowman M, et al. Who progresses to third-line therapies for overactive bladder? Trends from the AQUA Registry. *Urol Prac*. 2024;11(2):394-401.
6. Whitehead WE, Borrud L, Goode PS, et al. Fecal incontinence in US adults: epidemiology and risk factors. *Gastroenterol*. 2009;137(2):512-517.
7. Ditah I, Devaki P, Luma HN et al. Prevalence, trends, and risk factors for fecal incontinence in United States adults, 2005-2010. *Clin Gastroenterol Hepatol*. 2014;12:636-643.
8. Coyne KS, Cash B, Kopp Z, et al. The prevalence of chronic constipation and fecal incontinence among men and women with symptoms of overactive bladder. *BJU Int*. 2011;107(2):254-261.
9. M028930C001RevC – Altaviva™ Model P7850N Neurostimulator Implant Manual.
10. M028929C001RevC – Clinician Therapy and Programming Guide Altaviva™ Model P7850N.
11. Siegel S, Noblett K, Mangel J, et al. Five-year follow-up results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation. *J Urol*. 2018;199(1):229-236.
12. Medtronic InterStim™ Clinical Summary 2018.
13. Hull T, Giese C, Wexner SD, Mellgren A, Devroede G, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum. 2013;56:234–245.
14. NDHF1534-200202, Marketing claim data summary: Axonics vs Medtronic Basic Evaluation Lead, October 2020. Medtronic data on file.
15. Elterman D, Michaels J, Margolis E, et al. Prospective, multicenter study to evaluate performance and safety of a re-engineered temporary lead for InterStim™ therapy evaluation. *Neurourol Urodyn*. 2022;1-8.
16. Medtronic MRI Guidelines for InterStim™ systems, M980291A032 Rev A.
17. Axonics™ MRI guidelines, US, 110-0092-001rAM. Updated February 2024.
18. MDT-103.
19. MDT-301.
20. Kobashi K, Khandwala S, MacDiarmid S, et al. A prospective study to evaluate efficacy with the NURO percutaneous tibial neuromodulation system in drug naïve patients with overactive bladder syndrome (OAB). Presented at the American Urological Association 2018 Annual Meeting. *J Urol*. 2018;199(4) Supplement, Page e987.
21. Medtronic data on file: Market data 2025.

Medtronic

710 Medtronic Parkway
Minneapolis, MN 55432-5604

Tel: (763) 514-4000
Fax: (763) 514-4879

medtronic.com

Toll-free 1 (800) 328-2518
(24-hour technical support for
physicians and medical professionals)